Dividend Information About Quest Diagnostics: Key Insights Ahead of Oct 3, 2025 Ex-Dividend Date

Quest Diagnostics (DGX) has recently announced a cash dividend of $0.80000000 per share, with the ex-dividend date set for Oct 3, 2025. The dividend was declared on Aug 13, 2025, and is scheduled to be paid on Oct 20, 2025. This latest payout is significantly higher than the average of the last 10 dividend per share amounts, which stood at approximately $0.3554023. The company previously paid a similar cash dividend of $0.80000000 per share on Jul 21, 2025. With this most recent increase, investors should note the company's growing commitment to returning value to shareholders, as reflected in its consistent and now elevated dividend payments.

Recently, Quest Diagnostics made notable appearances at key industry events, further highlighting its strategic positioning in the healthcare sector. On Sept 29, 2025, the company participated in the Jefferies 2025 Healthcare Services Conference, where it outlined its strategic growth plans. Over the past week, this event has drawn considerable attention from investors and analysts, who are keen to understand how the company plans to leverage innovation and market expansion in the coming year. As of late, there has also been heightened interest in the company’s upcoming financial results, which are set to be released on Oct 21, 2025. This announcement has kept the stock in the spotlight, with many observers eager to see how Quest Diagnostics is performing against its quarterly expectations.

Since the last update, the stock price of Quest Diagnostics has remained relatively stable. As of Sept 26, 2025, the stock was trading at $188.99, showing minimal volatility in the short term. However, a recent discounted cash flow analysis suggests that the stock is undervalued by as much as 38.6%, indicating potential upside for long-term investors. These insights, combined with the company’s upcoming earnings report and strategic conference participation, suggest that Quest Diagnostics is in a strong position to continue delivering value to shareholders.

In conclusion, investors considering Quest Diagnostics ahead of the ex-dividend date on Oct 3, 2025, should note that this is the last day to purchase the stock and be eligible for the dividend. Any purchase made after this date will not entitle the investor to the dividend payment. With a strong recent performance and clear strategic direction, Quest Diagnostics remains a compelling option for those looking to benefit from both its dividend payouts and long-term growth potential.